Perimeter Medical Imaging AI Updates Investors on Advances in OCT Technology and AI | | Ai in healthcare examples | | Turtles AI

CEO Adrian Mendes to present live on June 12 at 12:30 p.m. ET on Perimeter Medical Imaging AI’s state of the art, including advances in OCTS-Series and B-Series with AI technology, clinical developments, and CPRIT-funded strategy.

Key Points:

• Date and Time: June 12, 2025, 12:30 p.m. ET, LifeSciences Virtual Investor Forum. 
• Available for streaming and archived for approximately 90 days on Perimeter’s website. 
• Highlights clinical progress of B-Series OCT device with ImgAssistAI 2.0: ASBrS 2025 trial with statistically significant results (p=0.0050). 
• FDA-cleared S-Series system offers intraoperative cellular imaging; B-Series remains investigational and limited in the U.S.

Perimeter Medical Imaging AI, based in Toronto and Dallas, will speak at the Life Sciences Virtual Investor Forum on Thursday, June 12, 2025 at 12:30 p.m. ET, through a live presentation that will be recorded and available for viewing for approximately 90 days on the Investor section of the company website. CEO Adrian Mendes will discuss the company’s operational and strategic advances, with a focus on intraoperative imaging systems based on optical coherence tomography (OCT).

The Perimeter S-Series, already FDA-cleared with 510(k) general indication clearance, provides real-time, cross-sectional cellular-level views of excised tissue to support immediate surgical decision making. While not specifically evaluated for breast tissue or reduction of re-excisions, it is an advanced tool for quality of care.

Significant advances were achieved with the Perimeter B-Series OCT integrated with ImgAssistAI 2.0, an investigational device designated “breakthrough” and the subject of a pivotal clinical trial supported by up to $7.4 million in funding from the Cancer Prevention and Research Institute of Texas. Results, presented at ASBrS 2025, showed that the system detected residual disease in 40% of patients after the standard procedure, with margin accuracy of 88.1%, while removing only 3.8% of additional tissue. The trial enrolled 206 patients and met the primary endpoint with statistical significance (p=0.0050). A premarketing application for use during breast-conserving procedures in the US was filed in March 2025.

During the virtual presentation, Mendes may update on recent clinical partnerships, such as the expansion of the S-Series into hospitals in New Mexico and Tennessee, or the launch of the OCT-Tissue registry, designed to fuel further advances in AI and imaging.

The presentation is part of an ongoing communication with investors: the recording will be viewable for approximately three months; in the meantime, management is actively sharing white papers (for example, on the decline in re-operation rates with OCT) and promoting live demos at medical conferences such as ASBrS or LSI USA.

The presentation on June 12 will provide an in-depth look at the state of progress of Perimeter Medical Imaging AI’s OCT technologies, the clinical validation of the devices, and regulatory implications, in a single strategic summary.

The event will provide an integrated overview of the company’s evolution and expected results on the regulatory and commercial front.